Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Common Equity: 2022-2025

Historic Common Equity for Immunocore Holdings (IMCR) over the last 2 years, with Sep 2025 value amounting to $396.6 million.

  • Immunocore Holdings' Common Equity rose 4.96% to $396.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.6 million, marking a year-over-year increase of 4.96%. This contributed to the annual value of $360.7 million for FY2024, which is 2.20% down from last year.
  • Immunocore Holdings' Common Equity amounted to $396.6 million in Q3 2025, which was up 2.08% from $388.5 million recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Common Equity registered a high of $396.6 million during Q3 2025, and its lowest value of $338.9 million during Q4 2022.
  • Moreover, its 3-year median value for Common Equity was $373.3 million (2023), whereas its average is $373.7 million.
  • As far as peak fluctuations go, Immunocore Holdings' Common Equity increased by 8.83% in 2023, and later declined by 2.20% in 2024.
  • Quarterly analysis of 4 years shows Immunocore Holdings' Common Equity stood at $338.9 million in 2022, then increased by 8.83% to $368.8 million in 2023, then dropped by 2.20% to $360.7 million in 2024, then grew by 4.96% to $396.6 million in 2025.
  • Its last three reported values are $396.6 million in Q3 2025, $388.5 million for Q2 2025, and $378.5 million during Q1 2025.